KRAS and lung cancer: With the development of KRAS inhibitors and combination strategies of KRAS inhibition with immunotherapy and other targeted therapies, there is an unmet need of characterizing the clinical and molecular features of KRAS-mutated lung cancer patients treated with immunotherapy to facilitate pre-clinical investigations and clinical development.